Αποτελέσματα Αναζήτησης
9 Σεπ 2024 · We conducted a systematic review of evidence on the efficacy and safety of a two-dose regimen (10 µg per dose) of Pfizer-BioNTech COVID-19 vaccine in children aged 5─11 years. We assessed outcomes and evaluated the quality of evidence using a modified GRADE approach.
30 Δεκ 2021 · The Advisory Committee on Immunization Practices (ACIP) recommends the Pfizer-BioNTech COVID-19 vaccine for children aged 5–11 years for the prevention of COVID-19 (6).
5 Σεπ 2024 · The Moderna COVID-19 vaccine is recommended for children 6 months through 5 years of age under an Emergency Use Authorization. ACIP recommends the intervention. The Pfizer-BioNTech COVID-19 vaccine is recommended for children 6 months through 4 years of age under an Emergency Use Authorization.
FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age. The FDA amended the emergency use authorizations (EUAs) of the updated (bivalent) Moderna and...
The US Food and Drug Administration (FDA) granted Emergency Use Authorization for Pfizer-BioNTech’s mRNA COVID-19 vaccine (BNT162b2) for children 5 to 11 years of age on October 29, 2021. The Centers for Disease Control and Prevention recommended use of the vaccine among children in this age group on November 2, 2021.
This study was conducted under the US Food and Drug Administration (FDA) Biologics Effectiveness and Safety (BEST) Initiative using rapid cycle analysis, or a near–real-time monitoring framework, which enables early detection of potential safety signals.
12 Νοε 2021 · On October 29, 2021, FDA issued an EUA amendment for a new formulation of Pfizer-BioNTech COVID-19 vaccine for use in children aged 5-11 years, administered as 2 doses (10 μg, 0.2 mL each), 3 weeks apart (Table) (1).
